Abstracts tagged "Juvenile idiopathic arthritis (JIA) and uveitis"

Abstract Number: 2726 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis
Jessica Shantha¹, Amy Cassedy ², Joseph McDonald ³, Theresa Hennard ⁴, Najima Mwase ⁵, Steven Yeh ¹ and Sheila Angeles-Han ⁶, ¹Emory University, Atlanta, GA, ²Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: Uveitis is a heterogenous group of ocular inflammatory diseases. Underlying disease and treatment can lead to poor quality of life (QOL), depression, and increased…
Abstract Number: 2408 • 2018 ACR/ARHP Annual Meeting
Comparison of the Tear Cytokine and Chemokine Profile of Children with JIA and JIA-Associated Uveitis
Sheila Angeles-Han¹, Virginia Miraldi Utz², Sherry Thornton³, Alyssa Sproles³, Najima Mwase⁴, Theresa Hennard³, Mekibib Altaye⁴ and Gary Holland⁵, ¹Rheumatology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ²Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Children with JIA are at increased risk for uveitis. Known risk factors do not accurately stratify risk. Biomarkers are needed to predict uveitis development…
Abstract Number: 977 • 2018 ACR/ARHP Annual Meeting
Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
Andrew Fell¹, Emma Carson¹, Gillian Coyle¹, Neil Martin¹, Jo Walsh¹ and Janet Gardner-Medwin², ¹Paediatic Rheumatology, Royal hospital for Children, Glasgow, United Kingdom, ²School of Medicine, Dentistry & Nursing, Child Health, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Original Reference Product (ORP) Infliximab lost market exclusivity in europe in early 2015. The Scottish National Health service (SNHS), runs a national procurement system…
Abstract Number: 2299 • 2017 ACR/ARHP Annual Meeting
Clinical Features and Characteristics of Juvenile Idiopathic Arthritis-Associated Uveitis in Japan：the First Report from the Pediatric Rheumatology Association of Japan (PRAJ)
Junko Yasumura¹, Masato Yashiro², Nami Okamoto³, Kosuke Shabana⁴, Hiroaki Umebayashi⁵, Naomi Iwata⁶, Tomohiro Kubota⁷, Mao Mizuta⁸, Kenichi Nishimura⁹, Yuka Okura¹⁰, Masaki Shimizu⁸, Minako Tomiita¹¹, Syuji Takei⁷ and Masaaki Mori¹², ¹Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan, ²Department of Pediatrics, Okayama University Hospital, Okayama, Japan, ³Pediatrics, Graduate School of Medicine, Osaka Medical College, Takatsuki, Japan, ⁴Department of Pediatrics, Graduate School of Medicine, Osaka Medical College, Takatsuki, Japan, ⁵Department of Rheumatics, Miyagi Children’s Hospital, Sendai, Japan, ⁶Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, Obu, Japan, ⁷Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ⁸Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ⁹Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹⁰Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Japan, ¹¹Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan, ¹²Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Several reports examined ethnic differences of Juvenile Idiopathic Arthritis -associated uveitis (JIA-U), however, there were no information from Japan. Therefore, PRAJ underwent multi-center surveillance…
Abstract Number: 2318 • 2017 ACR/ARHP Annual Meeting
Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy
Eileen Pagano¹, Myriam Kline² and B. Anne Eberhard³, ¹Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ²Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ³Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY
Background/Purpose: Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-a). It is known to be effective and often used in the…
Abstract Number: 2323 • 2017 ACR/ARHP Annual Meeting
Exploring HLA-DRB1 Risk Alleles in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis
Lai Hin Kimi Chan¹, Courtney McCracken¹, Kirsten Jenkins², Steven Yeh³, Purnima Patel⁴, Sampath Prahalad⁵ and Sheila Angeles-Han⁶, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Pediatrics, Emory Children's Center, Atlanta, GA, ⁶Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH
Exploring HLA-DRB1 Risk Alleles in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior UveitisBackground/Purpose: HLA-DRB1*08, 11 and 13 are risk alleles associated…
Abstract Number: 68 • 2017 Pediatric Rheumatology Symposium
HLA-DRB1 in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis
Lai Hin Kimi Chan¹, Courtney McCracken¹, Kirsten Jenkins², Steven Yeh³, Purnima Patel⁴, Sampath Prahalad¹ and Sheila Angeles-Han⁵, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: HLA-DRB1*08, 11 and 13 are strong risk alleles for various juvenile idiopathic arthritis (JIA) subtypes. We reported that carriage of DRB1*11 and *13 increased…
Abstract Number: 2427 • 2016 ACR/ARHP Annual Meeting
Identification of Biomarkers Using Tear Proteomics in Children with Chronic Anterior Uveitis
Sheila Angeles-Han^1,2, Duc Duong³, Steven Yeh⁴, Purnima Patel¹, Kirsten Jenkins², Sampath Prahalad^2,5 and Gary Holland⁶, ¹Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁶Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) are at risk for anterior uveitis which can lead to ocular complications and vision loss. The ANA is…
Abstract Number: 2901 • 2014 ACR/ARHP Annual Meeting
Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis
Gabriele Simonini¹, Claudia Bracaglia², Marco Cattalini³, Andrea Taddio⁴, Alice Brambilla⁵, Cinzia DeLibero⁶, Denise Pires Marafon⁷, Roberto Caputo⁶ and Rolando Cimaz¹, ¹Pediatric Rheumatology, Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ²Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³Pediatric Clinic, Spedali Civili di Brescia and University of Brescia, Pediatric Immunology and Rheumatology Unit, Brescia, Italy, ⁴Institute of Child Health, IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy, ⁵Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ⁶Ophthalmology Unit, Anna Meyer Children's Hospital, Florence, Italy, ⁷Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
Background/Purpose Information regarding the natural clinical history of a child on systemic treatment due to auto-immune chronic uveitis would be helpful in driving duration therapy.…
Abstract Number: 295 • 2013 ACR/ARHP Annual Meeting
Uveitis In The Nordic Juvenile Idiopathic Arthritis Cohort; High Incidence, Frequent Complications, and Gender Associated Risk Factors
Ellen Nordal^1,2, Lillemor Berntson³, Kristiina Aalto⁴, Suvi Peltoniemi⁵, Susan Nielsen⁶, Troels Herlin⁷, Anders Fasth⁸ and Marite Rygg^9,10, ¹Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ²Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, ³Department of Pediatrics, Uppsala University Hospital, Uppsala, Sweden, ⁴Department of Pediatrics,, Helsinki University Children's Hospital, Helsinki, Finland, ⁵Department of Pediatrics, Helsinki University Children's Hospital, Helsinki, Finland, ⁶Pediatric Rheumatology Unit, Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark, ⁷Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁸Department of Pediatrics, University of Gothenburg, Gothenburg, Sweden, ⁹Department of Laboratory Medicine, Children's and Women's health, Norwegian University of Science and Technology, Trondheim, Norway, ¹⁰Department of Pediatrics, St Olav University Hospital, Trondheim, Norway
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). Both incidence and reported outcome varies, and population-based data are scarce. Early…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].